VetSheet

表阿黴素

Epirubicin

4'-Epi-doxorubicin

抗腫瘤藥 - 蒽環類IV狗貓

別名: Pharmorubicin · 4'-Epi-doxorubicin · Epirubicinum

由 VetSheet 獸醫團隊審訂更新於 2026年4月5日本內容以實證獸醫文獻為本

30 mg/m2 (In dogs weighing <10 kg a dose of 1 mg/kg should be used)IV· q3wk· Maximum total dose not to exceed 240 mg/m2

這是按體表面積（mg/m²）計算的劑量；給藥前須先把體重換算為體表面積。

劑量為持牌獸醫專業人員的臨床參考。請務必對照最新藥品說明書及個別病患確認。

各物種劑量

🌎 NA — North America🌍 EU — Europe

狗

適應症劑量途徑頻次療程地區
Lymphoma, splenic haemangiosarcoma, histiocytic sarcoma, and other sarcomas/carcinomas30 mg/m2 (In dogs weighing <10 kg a dose of 1 mg/kg should be used)IVq3wkMaximum total dose not to exceed 240 mg/m2🌍 EU
  • Lymphoma, splenic haemangiosarcoma, histiocytic sarcoma, and other sarcomas/carcinomas: Administer over a minimum period of 10 minutes into the side port of a freely running IV infusion of 0.9% NaCl.

貓

適應症劑量途徑頻次療程地區
Feline injection site sarcoma25 mg/m2 or 1 mg/kgIVq3wk—🌍 EU
  • Feline injection site sarcoma: Administer over a minimum period of 10 minutes into the side port of a freely running IV infusion of 0.9% NaCl.

劑量為持牌獸醫專業人員的臨床參考。請務必對照最新藥品說明書及個別病患確認。

正在為病患診症？VetSheet 的 AI 會把藥物、劑量與療程直接寫入結構化診症筆記。了解 VetSheet 如何運作

概覽

​表阿黴素 (Epirubicin)​ 是多柔比星 (Doxorubicin) 的半合成立體異構物，在獸醫腫瘤學中用於治療多種腫瘤（如淋巴瘤和肉瘤）。

​臨床警告：​ 本藥為強效發泡劑。若發生血管外滲漏，將導致嚴重的組織壞死。必須透過妥善固定的留置靜脈導管給藥。

作用機制

Epirubicin enters the cell where its intracellular metabolism results in the production of cytotoxic free radicals. It also binds irreversibly to DNA → prevents DNA replication and alters cell membrane functions, ultimately leading to cell death.

安全性與警告

禁忌症

  • No specific absolute contraindications listed, but use with extreme caution in patients with pre-existing cardiac disease or the ABCB1 (MDR1) mutation.

不良反應

  • Acute anaphylaxis
  • Dose-dependent cumulative cardiotoxicity (cardiomyopathy, congestive heart failure)
  • Tachycardia and arrhythmias (during administration)
  • Anorexia
  • Vomiting
  • Pancreatitis
  • Severe leucopenia
  • Thrombocytopenia
  • Haemorrhagic gastroenteritis
  • Nephrotoxicity
  • Severe tissue necrosis (if extravasated)

注意事項

​Extravasation Risk:​ Severe tissue necrosis will occur if extravasated. Use of an indwelling catheter taped in place is essential. Administer into the side port of a freely running IV infusion of 0.9% NaCl over a minimum of 10 minutes. ​Cardiotoxicity:​ May cause dose-dependent cumulative cardiotoxicity, though possibly at a lower incidence than doxorubicin. Caution in patients with pre-existing cardiac disease. ​Myelosuppression:​ Suspend treatment if neutrophils drop below 2.5 × 10^9/L or platelets below 50 × 10^9/L. Reduce dose by 10-25% if haematological or GI toxicity is recurrent. ​Genetics:​ Dogs with the ​ABCB1 (MDR1)​ mutation may be at higher risk of toxicity.

​Clinical Pearl:​ Premedication with IV chlorphenamine or dexamethasone is recommended to prevent acute anaphylactic reactions.

藥物相互作用

HeparinMajor

Incompatible; a precipitate will form if mixed.

CyclophosphamideMajor

Increased risk of myelosuppression when used in combination.

CimetidineMajor

Increases the area under the dose curve (AUC) of epirubicin by 50%; should not be used concurrently.

監測

  • Complete Blood Count (CBC) and platelet count prior to every dose
  • Physical examination and auscultation
  • Electrocardiogram (ECG)
  • Echocardiogram (especially in breeds predisposed to cardiac disease)
  • Renal parameters
  • Gastrointestinal signs

藥物動力學

吸收

Administered intravenously, resulting in 100% bioavailability.

分佈

Rapidly distributed into tissues. Does not cross the blood-brain barrier effectively.

代謝

Extensively metabolized in the liver.

排除

Primarily eliminated via biliary excretion, with a smaller portion excreted in the urine.

過量

Overdosage increases the risk of severe myelosuppression, severe gastrointestinal toxicity (haemorrhagic gastroenteritis), and acute cardiotoxicity. Treatment is supportive and symptomatic, including aggressive fluid therapy, broad-spectrum antibiotics (if neutropenic), and antiemetics.

可用產品

劑型

  • 10 mg powder for reconstitution
  • 20 mg powder for reconstitution
  • 50 mg powder for reconstitution
  • 2 mg/ml solution

人用標示

  • Pharmorubicin
  • Epirubicin 10 mg, 20 mg, 50 mg powder for reconstitution
  • Epirubicin 2 mg/ml solution

各地核准狀態

European Union✓ 已核准處方藥EMA

Human authorized products used off-label under the cascade.

United Kingdom✓ 已核准處方藥 · POMVMD

Human authorized products used off-label under the cascade.

暫無法規資料: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU

儲存與穩定性

After reconstitution, the drug is stable for 24 hours at room temperature. Store under refrigeration up to 28 days. Protection from light is not necessary.

飼主須知

表阿黴素是一種用於治療寵物癌症的強效化療藥物。

  • ​排泄物處理：​ 化療藥物具有潛在危險性。治療後幾天內，請遵照獸醫指示處理寵物的排泄物（尿液/糞便）。
  • ​副作用：​ 請密切觀察寵物是否出現食慾不振、嘔吐或腹瀉。若有上述症狀，請立即聯繫獸醫。
  • ​心臟健康：​ 此藥物偶爾會影響心臟功能，獸醫可能會建議在治療前後進行心臟監測（如心電圖或超音波）。
  • ​感染風險：​ 寵物的白血球數量可能會下降，增加感染風險。請避免讓牠們接觸生病的動物。

VetSheet 藥物參考供持牌獸醫專業人員作臨床決策輔助之用，不能取代專業判斷或廠方最新藥品說明書。